Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEG-rhG-CSF and rhG-CSF in the Adjuvant Therapy of Aplastic Anemia Granulocyte Deficiency
NCT05531279Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jun 2022
- Primary completion
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of pegfilgrastim in aplastic anemia (3 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Total number of effective (ANC>0.5x10^9/L) days at 2 weeks. Started Jun 2022; status: recruiting.
02
Drugs
pegfilgrastim
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on NCT05531279.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05531279.